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Summary
Recent advances in molecular imaging and nanotechnology are providing new opportunities for 
biomedical imaging with great promise for the development of novel imaging agents. The unique 
optical, magnetic, and chemical properties of materials at the scale of nanometers allow the 
creation of imaging probes with better contrast enhancement, increased sensitivity, controlled 
biodistribution, better spatial and temporal information, multi-functionality and multi-modal 
imaging across MRI, PET, SPECT, and ultrasound. These features could ultimately translate to 
clinical advantages such as earlier detection, real time assessment of disease progression and 
personalized medicine. However, several years of investigation into the application of these 
materials to cancer research has revealed challenges that have delayed the successful application 
of these agents to the field of biomedical imaging. Understanding these challenges is critical to 
take full advantage of the benefits offered by nano-sized imaging agents. Therefore, this article 
presents the lessons learned and challenges encountered by a group of leading researchers in this 
field, and suggests ways forward to develop nanoparticle probes for cancer imaging. Published by 
Elsevier Ltd.
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Recent advances in molecular imaging and nanotechnology are providing new opportunities 
for biomedical imaging with great promise for the development of agents to address clinical 
needs for disease staging, stratification, and monitoring of responses to therapy [1]. 
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Materials at the scale of nanometers possess unique optical, magnetic, and chemical 
properties which allow the creation of imaging probes with increased signal density, signal 
amplification and quantification, improved contrast, and controlled biodistribution.
In 2011, the NCI Office of Cancer Nanotechnology Research (OCNR) assembled an 
imaging working group comprised of researchers working in the field of nanoparticle-based 
cancer imaging with the task of reviewing the current status of the field and identifying 
challenges associated with developing nanoparticle-based cancer imaging probes and 
bringing them into the clinic. In this article, we examine the current issues and challenges 
associated with nanotechnology-based imaging, and suggest opportunities for development 
of nanoparticle-based cancer imaging modalities.
Limitations of current nanoparticle imaging probes
An ideal nanoparticle imaging probe for clinical use should be biodegradable or rapidly 
excreted and have a low toxicity while producing a strong imaging signal. Several common 
issues shared among different nanoparticles compromise their further transition into clinical 
use.
Barriers for effective tumor delivery
Prior to reaching the tumor target, nanoparticles administered through intravenous injection 
interact with a complex environment that has evolved to seek out and exclude foreign 
matter. Primary obstacles to effective delivery of nanoparticles into tumors include 
clearance by the mono-nuclear phagocyte system (MPS) [2] and the heterogeneity of the 
tumor microenvironment, particularly in regards to physiological barriers such as antigen 
expression, and vascular and tumor permeability, which prevent both accumulation of 
sufficient quantities and uniform delivery of drugs and nanoparticles to all regions of tumors 
[3]. After entering the blood circulation, nanoparticles often bind plasma proteins 
(opsonization) and are taken up by phagocytic cells in the blood, liver, spleen and bone 
marrow. This MPS clearance presents two challenges: first it effectively removes 
nanoparticles from circulation and thus leaves a small fraction available for uptake at the 
tumor sites; second, it may lead to long retention times of potentially toxic nanoparticle 
components or metabolites, which presents significant concerns of off-target and chronic 
toxicities.
The tools available to mitigate these effects are limited. A commonly used approach to 
reducing MPS clearance and increasing circulation times is steric stabilization of particle 
dispersions by polyethylene glycol (PEG) coating. Long circulation times achieved by PEG-
coated “stealth” particles do not necessarily lead to enhanced accumulation deep into 
tumors, and PEG-coating may inhibit uptake of the nanoparticles by tumor cells. Current 
understanding of the effect of physicochemical characteristics of most nanoparticle 
constructs on their blood circulation times and body clearance is limited to basic parameters 
such as size and zeta-potential, while the role of other properties (shape, hydrophobicity, 
rigidity, etc.) is less understood. A significant effort is needed to create particles with 
optimal characteristics associated with both tumor specific accumulation and body 
clearance.
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Imaging very small tumors
A key advantage of using nanoparticle imaging agents as compared to small molecules is the 
opportunity for preferential localization at the disease site through enhanced permeability 
and retention (EPR). When a tumor reaches a certain size (typically over 1 mm in diameter), 
its vasculature becomes leaky and its lymphatic drainage system is dysfunctional, as well. 
Nanoparticles with long blood circulation times will tend to accumulate in the tumor 
interstitial space after moving across the leaky tumor blood vessels. The size of the gap 
openings of tumor vasculature is usually in the range of 400—600 nm, which is much larger 
than that found in most normal tissues [3,4].
It is generally agreed that targeting ligands facilitate the internalization of nanoparticles by 
target cells and increase their retention in tumors. However, it is unclear if any nanoparticle-
based strategy can enhance detection of the smallest tumors that do not possess a leaky 
tumor vasculature that favors EPR. Resolving these questions will require parallel 
developments in the identification of better targeting moieties and nanoparticle design.
Immunology
Immunological reactivity is a common toxicity observed with the clinical use of most 
contrast agents currently approved for diagnostic imaging. In addition to the immune 
reactivity of the nanoplatform itself, combination with targeting ligands, repeated 
administration, and contamination with endotoxins and pyrogens during the manufacturing 
process, can further increase the likelihood for immunogenicity [5].
Blood compatibility tests are required for nanoparticles distributed within the systemic 
circulation by the FDA before initiating phase 1 clinical studies. This type of testing is 
focused on detecting acute toxicities mediated by particle effects on erythrocytes 
(hemolysis), platelets, leukocytes and coagulation factors (thrombogenicity) and 
complement system (anaphylaxis). Nanoparticle interference with traditional in vitro tests is 
a common challenge during this step [5]. Understanding of the correlation between in vitro 
and in vivo immunotoxicity assays for nanomaterials significantly aids in conducting 
preclinical studies [16].
Toxicology
The selective tissue distribution of targeted nanoparticles and the accumulation of some 
nanomaterials within organs of the MPS, both require greater toxicological evaluation. This 
is especially the case for biopersistant nanomaterials, such as some metallic particles, that 
may result in chronic toxicities. Due to delayed clearance and increased systemic circulation 
relative to conventional imaging agents, there is the potential issue for increased systemic 
exposure to toxic components of nanomaterial-based imaging agents [6,7]. Nanoparticles 
may form micron-scale aggregates upon injection into the circulation, leading to 
microcirculation compromise, particularly in the capillary beds of the lungs and can result in 
inflammation and granuloma formation [8]. It is important to investigate the aggregation 
tendency of intravenous nanoparticles in plasma, especially when agents are dosed at high 
particle concentrations, and also to evaluate the lung as a potential target organ.
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Hurdles on the road to the clinic
Clinical translation of nanoparticle-based imaging agents has been very challenging and 
many obstacles have yet to be overcome. In contrast to therapeutic delivery systems, which 
are administered after confirmed diagnosis of disease, imaging agents are often used for 
diagnostic purposes prior to confirmed diagnosis. Accordingly, the regulatory burden is 
much greater for imaging than for therapeutic agents in order to avoid needless toxicity to 
patients who might turn out to be healthy.
Regulatory considerations
While no new toxicities, specific to nanoparticles, have been reported [5,9], there is always a 
concern that the nanometer sizes may lead to toxic response even if the nanoparticle 
constituents are Food and Drug Administration (FDA) approved. At present, in order to 
receive investigational new drug (IND) or investigational device exemption (IDE) approval, 
the U.S. FDA requires similar preclinical data for nanoparticle-based therapeutic and 
imaging agents as for any other new therapeutic or diagnostic [10]. The scope of safety 
studies is determined by four main criteria: (1) mass dose, (2) route of administration, (3) 
frequency of use, and (4) biological, physical and effective half-lives [11]. For an imaging 
probe, it is necessary to demonstrate specificity and sensitivity using a clinically relevant 
dose, and evaluate in vitro and in vivo stability, systemic toxicity, and pharmacokinetics and 
pharmacodynamics [12].
Unlike small molecule agents, nanoparticle contrast agents usually have complex 
formulations and multiple components, which make it challenging for the production of the 
nanoparticles in a large scale with consistent quality using Good Manufacturing Practice 
(GMP). Furthermore, systemic biodistribution, toxicity, and clearance of each component of 
the nanoparticle core, surface coating, and targeting ligand should also be fully examined in 
appropriate animal models. To facilitate the regulatory review of nanotechnologies intended 
for cancer therapies and diagnostics, the National Cancer Institute (NCI) established the 
Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity 
testing of nanoparticles developed by the research community and facilitate their progress 
through the regulatory approval process.
Financial realities
Economic considerations present additional and significant challenges in translating 
nanoparticle imaging agents to the clinical setting. The cost-effectiveness of these agents 
will be critical to their commercialization. In clinical medicine, additional imaging 
information frequently does not translate into changes in patient management decisions. 
Successful nanoparticle-based imaging agents will possess clear and measurable advantages 
over existing small molecule agents.
A targeted nanoparticle imaging agent that demonstrates early detection of cancers or 
detection of micro-metastases could clearly justify its cost by allowing for early 
intervention. Nanoparticle imaging agents could also provide prognostic indicators of early 
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therapeutic effectiveness, allowing physicians to rapidly alter therapeutic strategies, 
personalizing care to the individual patient and improving overall response.
Another important consideration is the financial incentive for the commercialization of 
molecular imaging agents. Although the imaging agent market is projected to expand to 
approximately $14 billion by 2015, it is not clear whether nanoparticle agents will be 
financially beneficial for companies developing them [13]. Nanoparticle imaging agents face 
similar cost concerns as nanoparticle therapeutic agents; R&D costs are inherently high and 
insurers are becoming more prudent in their re-imbursement policies. Furthermore, due to 
the existing reimbursement policies for imaging agents, the incentives involved in 
developing imaging agents are far fewer than those of therapeutic agents. Poor sales of one 
nanoformulated iron oxide MRI contrast agent, Feridex, and the high barrier for securing 
regulatory approval for another, Combidex, have prompted their manufacturer to 
discontinue these products.
Opportunities
One of the most important advantages of nanoparticle imaging agents is their ability to 
anchor a large number of the same or different molecules. The multi-functional capabilities 
of nanoparticles can lead to tailor-made imaging agents for personalized medicine. Future 
nanoparticle imaging agents will include capabilities through appropriate functionalization 
that will classify tumor subtypes in highly heterogeneous tumors based on identifying 
genetic or epi-genetic markers with in vivo and ex vivo diagnostics leading to personalized 
therapies.
The ability for multi-functionalization perhaps offers the greatest potential for clinical use 
by enabling compatibility in multiple imaging modalities (e.g. MR/CT, MR/PET, optical 
imaging, and others) in a single nanoplatform. Multimodality imaging allows 
complementary information over different temporal and spatial scales or different resolution 
or detection ranges for the same marker acquired from probes that localize to the same place 
at the same time; this provides a far more detailed picture than otherwise would be available. 
There is a widely acknowledged lack of safe MRI contrast agents especially because of 
concerns over the safety. It is hoped that use of nanoconstructs using iron oxide 
nanoparticles (some of which are FDA approved) may overcome some of these safety 
concerns while increasing contrast enhancement and imaging efficacy.
Theranostic nanoparticles, defined as those that combine the capacity for tumor imaging 
with therapeutic efficacy and low toxicity, are a novel concept currently at the preclinical 
stage and may provide the opportunity for real-time imaging of tumors as patients are 
undergoing therapy. The ability to monitor early indicators of therapeutic response could 
permit adjustment of treatment regimens and personalization of care. Biotechnology and 
pharmaceutical companies have expressed a willingness to invest in theranostic agents 
because of their potential for becoming novel and effective cancer therapeutic agents. 
However, while there are strong scientific rationales and urgent clinical needs for 
developing image-guided and targeted drug delivery agents, regulatory approval of these 
multi-functional agents faces greater challenges due to their complexity.
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Nanotechnology is also driving the development of new tools and instruments that may have 
a broad impact on clinical medicine, even if nanotechnology imaging agents may not make 
their way into in vivo use. Nanomaterials combined with imaging are being developed for 
high throughput diagnostic assays and improved tumor biopsies. A significant area of 
increasing application is in ex vivo diagnostics using imaging agents such as quantum dots, 
where bio-compatibility is not a requirement. Advances in magnetic nanoparticles have also 
led to a new imaging modality based on direct detection of particles [14]. Nanomaterials are 
also being used to develop new X-ray sources [15].
Overall, nanotechnology offers the promise to revolutionize the field of medical imaging. 
The ability to image and treat simultaneously, the ability to enhance tumor detection, and the 
ability to have multiple contrast agents on a single platform may drastically change patient 
management. Despite the challenges associated with clinical translation that must be 
overcome, nanotechnology is anticipated to play a major role in future medical imaging. 
Because nanoparticle imaging agents possess many advantages over their small molecule 
counterparts, we anticipate nanoparticle molecular imaging agents will ultimately be 
successful in the clinic.
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